[The New York Times] Gilead, Maker of Hepatitis C Drug, Strikes Deal on Generics for Poor Countries

Gilead announced that it had struck agreements with seven Indian generic drug makers to sell lower-cost versions of its $1,000-a-pill Hepatitis C drug in poorer countries. The deals are intended to provide greater access to the medicine Sovaldi for most of the nearly 180 million infected worldwide with Hepatitis C who do not live in rich countries. Some 350,000 people die every year of Hepatitis C infections, most of them in middle- and low-income nations.

[button title=”Read More” link=”http://www.nytimes.com/2014/09/16/business/international/maker-of-hepatitis-c-drug-strikes-deal-on-generics-for-poor-countries.html?emc=edit_tnt_20140915&nlid=58462464&tntemail0=y&utm_campaign=KHN%3A+First+Edition&utm_source=hs_email&utm_medium=email&utm_c” target=”_blank” size=”” color=”” class=””]